Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders, held earlier today.  A total of 43,610,863 common shares representing 16.6% of the 262,749,836 issued and outstanding common shares of the Company as at the record date of January 16, 2023, were represented either in person or by proxy at the Meeting.

The following five nominees proposed by the Company were elected as Directors of Numinus to serve until the Company’s next Annual Meeting of Shareholders, or until their successors are elected or appointed.  Below is a summary of the voting results for the Directors elected:

In addition to the election of all nominees listed as Directors in the Management Information Circular, dated January 18, 2023, Numinus shareholders approved all other resolutions placed before the Meeting, including setting the number of directors of the Company at five, the appointment of Davidson & Company LLP as auditors for the Company for the ensuing year and approval of the Omnibus Equity Incentive Plan.

More information about the resolutions voted on at today’s Meeting of Shareholders is available in Numinus’ Management Information Circular, which can be found on SEDAR at www.sedar.com.  Final voting results on all matters voted on at the Meeting will also be filed on SEDAR.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.